Filing Details

Accession Number:
0001181431-11-030553
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-05-17 19:44:47
Reporting Period:
2011-05-13
Filing Date:
2011-05-17
Accepted Time:
2011-05-17 19:44:47
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
891288 Questcor Pharmaceuticals Inc QCOR Pharmaceutical Preparations (2834) 330476164
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1321073 Lahue Stephen Cartt 1300 North Kellogg Drive
Suite D
Anaheim CA 92807
Executive Vp & Cbo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-05-13 506 $0.98 78,704 No 4 M Direct
Common Stock Acquisiton 2011-05-13 50,000 $0.46 128,704 No 4 M Direct
Common Stock Acquisiton 2011-05-13 19,894 $0.98 148,598 No 4 M Direct
Common Stock Disposition 2011-05-13 70,400 $22.73 78,198 No 4 S Direct
Common Stock Acquisiton 2011-05-16 79,087 $0.98 157,285 No 4 M Direct
Common Stock Disposition 2011-05-16 79,087 $22.04 78,198 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2011-05-13 506 $0.00 506 $0.98
Common Stock Stock Option (Right to Buy) Disposition 2011-05-13 50,000 $0.00 50,000 $0.46
Common Stock Stock Option (Right to Buy) Disposition 2011-05-13 19,894 $0.00 19,894 $0.98
Common Stock Stock Option (Right to Buy) Disposition 2011-05-16 79,087 $0.00 79,087 $0.98
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2016-02-26 No 4 M Direct
0 2015-03-07 No 4 M Direct
0 2016-02-26 No 4 M Direct
0 2016-02-26 No 4 M Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.60-$22.82, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 1 of the Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00-$22.15, inclusive. The reporting person undertakes to provide Questcor Pharmaceuticals, Inc., any security holder of Questcor Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 2 of the Form 4.
  3. This amount includes 27, 243 vested shares of restricted stock and 50,955 shares of common stock. The reporting person currently has a total of 766,513 unexercised options granted at different dates and exercise prices consisting of 459,553 vested options and 306,960 unvested options.
  4. Incentive Stock option granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan on February 27, 2006.
  5. The option was fully vested and exercisable as of February 27, 2010.
  6. Incentive Stock option granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan on March 8, 2005.
  7. The option was fully vested and exercisable as of March 8, 2009.
  8. Non-Qualified Stock option granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan on February 27, 2006.
  9. The option was fully vested and exercisable as of December 27, 2007.
  10. Incentive Stock option granted under the Questcor Pharmaceuticals, Inc. 1992 Employee Stock Option Plan on February 27, 2006.
  11. The option was fully vested and exercisable as of February 27, 2010.